{"filing":{"accession_number":"0001104659-26-090086","cik":"0001802665","ticker":"HRMY","company_name":"Harmony Biosciences Holdings, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"hrmy-20260804x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804x8k.htm"},"events":[{"id":23824,"run_id":21549,"accession_number":"0001104659-26-090086","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Harmony Biosciences disclosed Q2 2026 financial results, reporting net product revenue of $261.3 million (30% YoY growth) and net income of $75.4 million ($1.28 per diluted share), while reiterating full-year 2026 WAKIX revenue guidance of $1.0–$1.04 billion.","company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24162,"accession_number":"0001104659-26-090086","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Harmony Biosciences. The press release announces net product revenue of $261.3 million (30% YoY growth), net income of $75.4 million ($1.28 per diluted share), and reiterates full-year 2026 WAKIX revenue guidance of $1.0–$1.04 billion. The filing is properly classified under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:20:12.801806+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24163,"accession_number":"0001104659-26-090086","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Q2 2026 financial results for Harmony Biosciences, including net product revenue of $261.3 million (30% YoY growth), net income of $75.4 million, and reiterates full-year 2026 WAKIX revenue guidance of $1.0–$1.04 billion. Although Item 7.01 (Regulation FD Disclosure) is cited, the substantive content in Exhibit 99.1 is a formal earnings announcement with detailed financial metrics, operating expense breakdowns, and cash position disclosures typical of an earnings release. This is material to investors assessing the registrant's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:20:12.801806+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24162,"accession_number":"0001104659-26-090086","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Harmony Biosciences. The press release announces net product revenue of $261.3 million (30% YoY growth), net income of $75.4 million ($1.28 per diluted share), and reiterates full-year 2026 WAKIX revenue guidance of $1.0–$1.04 billion. The filing is properly classified under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:20:12.801806+00:00","company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","filing_date":"2026-08-04"},{"id":24163,"accession_number":"0001104659-26-090086","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Q2 2026 financial results for Harmony Biosciences, including net product revenue of $261.3 million (30% YoY growth), net income of $75.4 million, and reiterates full-year 2026 WAKIX revenue guidance of $1.0–$1.04 billion. Although Item 7.01 (Regulation FD Disclosure) is cited, the substantive content in Exhibit 99.1 is a formal earnings announcement with detailed financial metrics, operating expense breakdowns, and cash position disclosures typical of an earnings release. This is material to investors assessing the registrant's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:20:12.801806+00:00","company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","filing_date":"2026-08-04"}]}